Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
RUSSO, Momtchilo
LINS, Bruna B.
KERSTEN, Victor
PERNAMBUCO, Paulo C. A.
GOMES, Brisa Moreira
DATI, Livia Mendonca Munhoz
Citação
VACCINES, v.11, n.11, article ID 1732, 17p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight loss and mortality indicators. However, when compared with subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta, and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine, which was more robust than homologous immunity.
Palavras-chave
SARS-CoV-2, vaccine, hACE2 transgenic mice, intranasal route, spike protein, cationic liposome, CpG-ODNs, heterologous immunity
URI
https://observatorio.fm.usp.br/handle/OPI/57956
Referências
  1. Afkhami S, 2022, CELL, V185, P896, DOI 10.1016/j.cell.2022.02.005
  2. Alameh MG, 2021, IMMUNITY, V54, P2877, DOI 10.1016/j.immuni.2021.11.001
  3. Alberca-Custodio RW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00692
  4. Alvim RGF, 2022, BIOCHEM ENG J, V186, DOI 10.1016/j.bej.2022.108537
  5. Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
  6. Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775
  7. Brandtzaeg P, 2009, SCAND J IMMUNOL, V70, P505, DOI 10.1111/j.1365-3083.2009.02319.x
  8. Castro JT, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-32547-y
  9. Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
  10. Collins FS, 2021, SCIENCE, V373, P165, DOI 10.1126/science.abj8547
  11. Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
  12. Diallo BK, 2023, NPJ VACCINES, V8, DOI 10.1038/s41541-023-00665-3
  13. Firmino-Cruz L, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10081305
  14. Halfmann PJ, 2022, NATURE, V603, P687, DOI 10.1038/s41586-022-04441-6
  15. Hand TW, 2021, ANNU REV IMMUNOL, V39, P695, DOI 10.1146/annurev-immunol-102119-074236
  16. Harder T, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.41.2100920
  17. Hartmann G, 2003, EUR J IMMUNOL, V33, P1633, DOI 10.1002/eji.200323813
  18. Hassan AO, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109452
  19. Hosseini ES, 2020, VIROLOGY, V551, P1, DOI 10.1016/j.virol.2020.08.011
  20. Israelow B, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abl4509
  21. Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583
  22. McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
  23. Mendes-Correa MC, 2023, VIRUSES-BASEL, V15, DOI 10.3390/v15061270
  24. Mendrone A, 2021, TRANSFUSION, V61, P1181, DOI 10.1111/trf.16268
  25. Mirotti LC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00047
  26. Nurtop E, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1105-5
  27. OGRA PL, 1984, REV INFECT DIS, V6, pS361
  28. Ou BS, 2023, bioRxiv, DOI [10.1101/2023.01.02.522505, 10.1101/2023.01.02.522505, DOI 10.1101/2023.01.02.522505]
  29. Präbst K, 2017, METHODS MOL BIOL, V1601, P1, DOI 10.1007/978-1-4939-6960-9_1
  30. Reigado GR, 2022, BIOTECHNOL APPL BIOC, V69, P2673, DOI 10.1002/bab.2314
  31. Rivera-Hernandez T, 2020, MBIO, V11, DOI 10.1128/mBio.00122-20
  32. See RH, 2006, J GEN VIROL, V87, P641, DOI 10.1099/vir.0.81579-0
  33. Sengupta A, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10040504
  34. Slavov SN, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14102148
  35. Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223
  36. Suzuki K, 2010, IMMUNITY, V33, P71, DOI 10.1016/j.immuni.2010.07.003
  37. Villas-Boas LS, 2022, CLINICS, V77, DOI 10.1016/j.clinsp.2022.100068
  38. Vollmer J, 2004, EUR J IMMUNOL, V34, P251, DOI 10.1002/eji.200324032
  39. Wang ZJ, 2022, J EXP MED, V219, DOI 10.1084/jem.20220826
  40. Wendel S, 2020, TRANSFUSION, V60, P2938, DOI 10.1111/trf.16065
  41. Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1126/science.abb2507, 10.1101/2020.02.11.944462]
  42. Zhang GF, 2022, J MED VIROL, V94, P5678, DOI 10.1002/jmv.28032
  43. Zhu Y, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/394578

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/05
Carregar mais